FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382811691> ?p ?o ?g. }

• W4382811691 endingPage "S56" @default.
• W4382811691 startingPage "S56" @default.
• W4382811691 abstract "Circulating tumor DNA (ctDNA) is emerging as a biomarker to detect molecular evidence of residual disease and predict recurrence in patients with colorectal cancer in the adjuvant setting. Treatment paradigms have been evolving in stage II and III rectal with total neoadjuvant therapy (TNT). Prospective evaluation, feasibility and the utility of using ctDNA as a biomarker during neoadjuvant therapy in clinical practice has been limited to date. In this retrospective single institution study, data from commercial ctDNA testing in 12 patients with rectal cancer during their neoadjuvant management was analyzed. A personalized and tumor-informed multiplex PCR assay (Signatera TM 16-plex bespoke mPCR NGS assay) was used for the detection and quantification of ctDNA. ctDNA testing was performed at the time of diagnosis and at completion of TNT. Primary objectives of the study are to determine the feasibility of tumor informed ctDNA testing in rectal cancer patients and the proportion of ctDNA positivity at diagnosis. Secondary objectives are to determine correlation of ctDNA response with clinical and pathologic responses. Agreement was assessed by concordance with 95% CI and was compared to 0.5 as a null hypothesis. ctDNA testing was performed in 12 patients; 1 patient did not have a pre-treatment test. Seven of the 11 evaluable patients were females and 4 patients were males. Ten out of 11 patients had at least T3 or T4 and N1 or N2 rectal cancer at presentation. Tumor-informed ctDNA was detected in 100% (11/11) of the patients at diagnosis. Ten patients had completed total neoadjuvant therapy with at least 2 time points of ctDNA testing. Six patients underwent rectal cancer surgery while 2 patients opted for a watch-and-wait approach. Nine out of 10 patients had a reduction in ctDNA levels with neoadjuvant therapy. Six out of 9 patients had cleared their ctDNA after TNT. The ctDNA clearance (N=6) correlated 100% (95% CI: 0.7-1.0, p=0.004) with overall clinical response (PR or CR), and the reduction in ctDNA levels (N=3) correlated with histologic evidence of treatment effect on definitive surgical pathology. Circulating tumor DNA was detected in 100% of rectal cancer patients at diagnosis prior to initiation of TNT. Clinical and pathological responses correlated with reduction or clearance in ctDNA. This study demonstrates the feasibility of tumor-informed ctDNA in patients with rectal cancer in the neoadjuvant setting. Further prospective data are required to determine the definitive utility of ctDNA as a correlative biomarker to assess clinical and pathological responses to neoadjuvant rectal cancer patient management." @default.
• W4382811691 created "2023-07-02" @default.
• W4382811691 creator A5017353282 @default.
• W4382811691 creator A5019609013 @default.
• W4382811691 creator A5045618241 @default.
• W4382811691 creator A5056209015 @default.
• W4382811691 creator A5077112675 @default.
• W4382811691 date "2023-06-01" @default.
• W4382811691 modified "2023-10-16" @default.
• W4382811691 title "P-117 Feasibility of tumor informed circulating tumor DNA in neoadjuvant rectal cancer" @default.
• W4382811691 doi "https://doi.org/10.1016/j.annonc.2023.04.173" @default.
• W4382811691 hasPublicationYear "2023" @default.
• W4382811691 type Work @default.
• W4382811691 citedByCount "0" @default.
• W4382811691 crossrefType "journal-article" @default.
• W4382811691 hasAuthorship W4382811691A5017353282 @default.
• W4382811691 hasAuthorship W4382811691A5019609013 @default.
• W4382811691 hasAuthorship W4382811691A5045618241 @default.
• W4382811691 hasAuthorship W4382811691A5056209015 @default.
• W4382811691 hasAuthorship W4382811691A5077112675 @default.
• W4382811691 hasBestOaLocation W43828116911 @default.
• W4382811691 hasConcept C121608353 @default.
• W4382811691 hasConcept C126322002 @default.
• W4382811691 hasConcept C143998085 @default.
• W4382811691 hasConcept C146357865 @default.
• W4382811691 hasConcept C151730666 @default.
• W4382811691 hasConcept C160798450 @default.
• W4382811691 hasConcept C185592680 @default.
• W4382811691 hasConcept C188816634 @default.
• W4382811691 hasConcept C2778292576 @default.
• W4382811691 hasConcept C2781188995 @default.
• W4382811691 hasConcept C2781197716 @default.
• W4382811691 hasConcept C2781335228 @default.
• W4382811691 hasConcept C526805850 @default.
• W4382811691 hasConcept C530470458 @default.
• W4382811691 hasConcept C55493867 @default.
• W4382811691 hasConcept C60644358 @default.
• W4382811691 hasConcept C71924100 @default.
• W4382811691 hasConcept C86803240 @default.
• W4382811691 hasConceptScore W4382811691C121608353 @default.
• W4382811691 hasConceptScore W4382811691C126322002 @default.
• W4382811691 hasConceptScore W4382811691C143998085 @default.
• W4382811691 hasConceptScore W4382811691C146357865 @default.
• W4382811691 hasConceptScore W4382811691C151730666 @default.
• W4382811691 hasConceptScore W4382811691C160798450 @default.
• W4382811691 hasConceptScore W4382811691C185592680 @default.
• W4382811691 hasConceptScore W4382811691C188816634 @default.
• W4382811691 hasConceptScore W4382811691C2778292576 @default.
• W4382811691 hasConceptScore W4382811691C2781188995 @default.
• W4382811691 hasConceptScore W4382811691C2781197716 @default.
• W4382811691 hasConceptScore W4382811691C2781335228 @default.
• W4382811691 hasConceptScore W4382811691C526805850 @default.
• W4382811691 hasConceptScore W4382811691C530470458 @default.
• W4382811691 hasConceptScore W4382811691C55493867 @default.
• W4382811691 hasConceptScore W4382811691C60644358 @default.
• W4382811691 hasConceptScore W4382811691C71924100 @default.
• W4382811691 hasConceptScore W4382811691C86803240 @default.
• W4382811691 hasLocation W43828116911 @default.
• W4382811691 hasOpenAccess W4382811691 @default.
• W4382811691 hasPrimaryLocation W43828116911 @default.
• W4382811691 hasRelatedWork W1985170944 @default.
• W4382811691 hasRelatedWork W2072537511 @default.
• W4382811691 hasRelatedWork W2280589513 @default.
• W4382811691 hasRelatedWork W2858928281 @default.
• W4382811691 hasRelatedWork W2913081698 @default.
• W4382811691 hasRelatedWork W2965269027 @default.
• W4382811691 hasRelatedWork W3097634536 @default.
• W4382811691 hasRelatedWork W3199290465 @default.
• W4382811691 hasRelatedWork W4220654808 @default.
• W4382811691 hasRelatedWork W4380368510 @default.
• W4382811691 hasVolume "34" @default.
• W4382811691 isParatext "false" @default.
• W4382811691 isRetracted "false" @default.
• W4382811691 workType "article" @default.